REVIEW
|
doi:10.20944/preprints202207.0256.v1
Subject:
Medicine And Pharmacology,
Oncology And Oncogenics
Keywords:
cancer; immunotherapy; adverse events; immune checkpoints inhibitors; chimeric antigen receptor therapy; bispecific antibodies; toxicity; renal; oncology
Online: 18 July 2022 (09:21:56 CEST)